StreetInsider.com News Articles

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Fri, 08 May 2026 07:00:00 -0400

Oxford, UK – 8 May 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT), taking place from 11-15 May in Boston.

OXB will exhibit at Booth #1331, where its commercial team will be available to discuss how OXB supports the development and manufacture of cell and gene therapies from pre-clinical through to commercialisation. Representing OXB onsite will be Sébastien Ribault, PhD, Chief Business Officer, alongside Business Development Directors Mark Marrano, Lisa Parenteau, and

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Fri, 08 May 2026 07:00:00 -0400

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Fri, 08 May 2026 07:00:00 -0400

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Fri, 08 May 2026 07:00:00 -0400

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Fri, 08 May 2026 07:00:00 -0400

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Fri, 08 May 2026 07:00:00 -0400

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Fri, 27 Mar 2026 08:00:00 -0400

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards in New York City.

The award forms part of the CDMO Leadership Awards’ Jury Awards, which recognise exceptional leadership, innovation and impact across the CDMO industry.

Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: “We are proud to receive this recognition for innovation at this year’s CDMO Leadership Awards. It reflects the strength of

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Fri, 27 Mar 2026 08:00:00 -0400

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards in New York City.

The award forms part of the CDMO Leadership Awards’ Jury Awards, which recognise exceptional leadership, innovation and impact across the CDMO industry.

Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: “We are proud to receive this recognition for innovation at this year’s CDMO Leadership Awards. It reflects the strength of

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Fri, 27 Mar 2026 08:00:00 -0400

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards in New York City.

The award forms part of the CDMO Leadership Awards’ Jury Awards, which recognise exceptional leadership, innovation and impact across the CDMO industry.

Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: “We are proud to receive this recognition for innovation at this year’s CDMO Leadership Awards. It reflects the strength of

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Fri, 27 Mar 2026 08:00:00 -0400

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards in New York City.

The award forms part of the CDMO Leadership Awards’ Jury Awards, which recognise exceptional leadership, innovation and impact across the CDMO industry.

Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: “We are proud to receive this recognition for innovation at this year’s CDMO Leadership Awards. It reflects the strength of

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Fri, 27 Mar 2026 08:00:00 -0400

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards in New York City.

The award forms part of the CDMO Leadership Awards’ Jury Awards, which recognise exceptional leadership, innovation and impact across the CDMO industry.

Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: “We are proud to receive this recognition for innovation at this year’s CDMO Leadership Awards. It reflects the strength of

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Fri, 27 Mar 2026 08:00:00 -0400

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO Leadership Awards in New York City.

The award forms part of the CDMO Leadership Awards’ Jury Awards, which recognise exceptional leadership, innovation and impact across the CDMO industry.

Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: “We are proud to receive this recognition for innovation at this year’s CDMO Leadership Awards. It reflects the strength of

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Wed, 29 Oct 2025 10:01:00 -0400

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs.

This recognition demonstrates OXB’s excellence in quality, innovation and service across its global network. It comes at a time of strong

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Wed, 29 Oct 2025 10:01:00 -0400

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs.

This recognition demonstrates OXB’s excellence in quality, innovation and service across its global network. It comes at a time of strong

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Wed, 29 Oct 2025 10:01:00 -0400

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs.

This recognition demonstrates OXB’s excellence in quality, innovation and service across its global network. It comes at a time of strong

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Wed, 29 Oct 2025 10:01:00 -0400

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs.

This recognition demonstrates OXB’s excellence in quality, innovation and service across its global network. It comes at a time of strong

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Wed, 29 Oct 2025 10:01:00 -0400

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs.

This recognition demonstrates OXB’s excellence in quality, innovation and service across its global network. It comes at a time of strong

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Wed, 29 Oct 2025 10:01:00 -0400

Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs.

This recognition demonstrates OXB’s excellence in quality, innovation and service across its global network. It comes at a time of strong

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Fri, 21 Mar 2025 08:00:00 -0400

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards.

The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma and biotechnology companies. The awards use feedback exclusively from experienced industry leaders to evaluate

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Fri, 21 Mar 2025 08:00:00 -0400

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards.

The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma and biotechnology companies. The awards use feedback exclusively from experienced industry leaders to evaluate

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Fri, 21 Mar 2025 08:00:00 -0400

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards.

The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma and biotechnology companies. The awards use feedback exclusively from experienced industry leaders to evaluate

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Fri, 21 Mar 2025 08:00:00 -0400

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards.

The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma and biotechnology companies. The awards use feedback exclusively from experienced industry leaders to evaluate

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Fri, 21 Mar 2025 08:00:00 -0400

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards.

The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma and biotechnology companies. The awards use feedback exclusively from experienced industry leaders to evaluate

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Fri, 21 Mar 2025 08:00:00 -0400

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category

Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards.

The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma and biotechnology companies. The awards use feedback exclusively from experienced industry leaders to evaluate

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis

Thu, 20 Feb 2025 08:36:00 -0400

OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis

Commencement of LENTICLAIR™ 1 trial, utilising OXB lentiviral vectors; builds on long term collaboration with Boehringer Ingelheim

Oxford, UK – 20 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim's newly initiated LENTICLAIR™ 1 trial. The Phase I/II study is evaluating BI 3720931, a novel, first-in-class, inhaled gene